BBC - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Clinical Trials ETF (BBC)
Rating:48Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating positive momentum in its clinical-stage biotech holdings.
Top Holdings Showing Solid Gains
Many of the largest positions, such as Erasca and several other biotech names, have delivered strong year-to-date performance that has supported the fund’s returns.
Targeted Exposure to Biotech Innovation
The fund focuses on clinical-trial-stage biotech companies, giving investors concentrated access to a high-innovation corner of the health care market.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so the ETF is heavily exposed to swings in biotech and pharmaceutical markets.
Limited Geographic Diversification
With nearly all holdings in U.S. companies, the fund offers little protection from U.S.-specific regulatory or market risks.
Above-Average Expense Ratio
The ETF’s fee is relatively high compared with many broad market funds, which can reduce net returns over time.
BBC vs. SPDR S&P 500 ETF (SPY)
AUM45.40M
RegionNorth America
Expense Ratio0.65%
Beta1.38
IssuerVirtus
Inception DateDec 16, 2014
Dividend Yield1.53%
Asset ClassEquity
Index TrackedLifeSci Biotechnology Clinical Trials Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume36,420
30 Day Avg. Volume23,658
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
87.21Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering122
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBC Summary
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) tracks the LifeSci Biotechnology Clinical Trials Index and focuses on U.S. health care companies working on new drugs and treatments in clinical trials. It mainly holds smaller biotech firms such as Relay Therapeutics and Kodiak Sciences that are trying to develop breakthrough medicines. Someone might invest in this ETF to seek growth from medical innovation and to get broad exposure to many biotech names instead of picking single stocks. However, this fund can be very volatile and its price can rise or fall sharply based on drug trial results and overall biotech market sentiment.
How much will it cost me?The Virtus LifeSci Biotech Clinical Trials ETF (Ticker: BBC) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the biotechnology sector that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Clinical Trials ETF could benefit from advancements in biotechnology and medical research, as well as increased funding for healthcare innovation in the U.S., where it is primarily focused. However, it may face challenges from regulatory hurdles, high costs associated with clinical trials, and potential setbacks in drug approvals, which could negatively impact the performance of its top holdings. Economic conditions, such as changes in interest rates or reduced investor appetite for high-risk sectors, could also influence the ETF's future performance.
BBC Top 10 Holdings
This ETF is a pure play on U.S. clinical-stage biotech, so it lives and dies by trial headlines rather than steady profits. Names like Tango Therapeutics, Enliven Therapeutics, and Spyre Therapeutics have been rising lately, giving the fund some welcome lift despite their early-stage risk. Oruka Therapeutics and Dianthus Therapeutics are also trending upward, helping reinforce that momentum. On the flip side, laggards such as Erasca and Corvus Pharmaceuticals are dragging on returns, a reminder that concentrated exposure to small health care names can be a bumpy ride.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Erasca | 2.14% | $999.06K | $3.50B | 821.31% | 34 Underperform | |
| Tango Therapeutics | 1.86% | $870.89K | $2.93B | 1000.00% | 59 Neutral | |
| Enliven Therapeutics | 1.86% | $869.31K | $2.53B | 153.29% | 36 Underperform | |
| Spyre Therapeutics | 1.65% | $773.36K | $6.43B | 393.34% | 43 Neutral | |
| Oruka Therapeutics | 1.59% | $742.25K | $3.66B | 453.52% | 41 Neutral | |
| Alumis Inc. | 1.52% | $708.97K | $2.81B | 351.69% | 43 Neutral | |
| Dianthus Therapeutics | 1.51% | $708.50K | $4.73B | 369.36% | 61 Neutral | |
| Corvus Pharmaceuticals | 1.41% | $661.13K | $1.06B | 261.32% | 41 Neutral | |
| Revolution Medicines | 1.37% | $639.71K | $32.22B | 281.09% | 52 Neutral | |
| Rezolute | 1.36% | $635.25K | $312.95M | -16.45% | 53 Neutral |
BBC Technical Analysis
Positive
―
Price Trends
43.33
Negative
42.16
Positive
35.84
Positive
Market Momentum
-0.48
Positive
45.87
Neutral
48.24
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 43.79, equal to the 50-day MA of 43.33, and equal to the 200-day MA of 35.84, indicating a neutral trend. The MACD of -0.48 indicates Positive momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 48.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBC.
BBC Peer Comparison
Comparison Results
Performance Comparison
BBC
Virtus LifeSci Biotech Clinical Trials ETF
42.71
25.29
145.18%
MILN
Global X Millennial Consumer ETF
―
―
―
GXPT
Global X PureCap MSCI Information Technology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents